Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

Nune Markosyan, … , Ben Z. Stanger, Robert H. Vonderheide


Resistance to immunotherapy is one of the biggest problems of current oncotherapeutics. While T cell abundance is essential for tumor responsiveness to immunotherapy, factors that define the T cell–inflamed tumor microenvironment are not fully understood. We used an unbiased approach to identify tumor-intrinsic mechanisms shaping the immune tumor microenvironment (TME), focusing on pancreatic adenocarcinoma because it is refractory to immunotherapy and excludes T cells from the TME. From human tumors, we identified ephrin-A receptor 2 (EPHA2) as a candidate tumor-intrinsic driver of immunosuppression. Epha2 deletion reversed T cell exclusion and sensitized tumors to immunotherapy. We found that prostaglandin endoperoxide synthase 2 (PTGS2), the gene encoding cyclooxygenase-2, lies downstream of EPHA2 signaling through TGF-β and is associated with poor patient survival. Ptgs2 deletion reversed T cell exclusion and sensitized tumors to immunotherapy; pharmacological inhibition of PTGS2 was similarly effective. Thus, EPHA2/PTGS2 signaling in tumor cells regulates tumor immune phenotypes; blockade may represent a therapeutic avenue for immunotherapy-refractory cancers. Our findings warrant clinical trials testing the effectiveness of therapies combining EPHA2/TGF-β/PTGS2 pathway inhibitors with antitumor immunotherapy and may change the treatment of notoriously therapy-resistant pancreatic adenocarcinoma.

Find the latest version:
http://jci.me/127755/pdf
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

Nune Markosyan,1 Jinyang Li,2 Yu H. Sun,3 Lee P. Richman,2 Jeffrey H. Lin,2 Fangxue Yan,2 Liz Quinones,2 Yogeve Sela,2 Taiji Yamazoe,2 Naomi Gordon,3 John W. Tobias,4 Katelyn T. Byrne,1,5 Andrew J. Rech,2,5 Garret A. FitzGerald,6,7 Ben Z. Stanger,1,2,5,8,9 and Robert H. Vonderheide,1,2,5,9,10

1Department of Medicine, 2Abramson Family Cancer Research Institute, 3Center for RNA Biology, Department of Biochemistry and Biophysics, Department of Urology, University of Rochester Medical Center, Rochester, New York, USA, 4Penn Genomic Analysis Core, 5Parker Institute for Cancer Immunotherapy, 6Department of Systems Pharmacology and Translational Therapeutics, 7Institute for Translational Medicine and Therapeutics, 8Department of Cell and Developmental Biology, 9Abramson Cancer Center, and 10Institute for Immunology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Resistance to immunotherapy is one of the biggest problems of current oncotherapeutics. While T cell abundance is essential for tumor responsiveness to immunotherapy, factors that define the T cell–inflamed tumor microenvironment are not fully understood. We used an unbiased approach to identify tumor-intrinsic mechanisms shaping the immune tumor microenvironment (TME), focusing on pancreatic adenocarcinoma because it is refractory to immunotherapy and excludes T cells from the TME. From human tumors, we identified ephrin-A receptor 2 (EPHA2) as a candidate tumor-intrinsic driver of immunosuppression. Epha2 deletion reversed T cell exclusion and sensitized tumors to immunotherapy. We found that prostaglandin endoperoxide synthase 2 (PTGS2), the gene encoding cyclooxygenase-2, lies downstream of EPHA2 signaling through TGF-β and is associated with poor patient survival. Ptgs2 deletion reversed T cell exclusion and sensitized tumors to immunotherapy; pharmacological inhibition of PTGS2 was similarly effective. Thus, EPHA2/PTGS2 signaling in tumor cells regulates tumor immune phenotypes; blockade may represent a therapeutic avenue for immunotherapy–refractory cancers. Our findings warrant clinical trials testing the effectiveness of therapies combining EPHA2/TGF-β/PTGS2 pathway inhibitors with antitumor immunotherapy and may change the treatment of notoriously therapy-resistant pancreatic adenocarcinoma.

Introduction
Immunotherapies, including immune checkpoint blockade (ICB), have led to significant improvement of clinical care for cancer patients (1–4). Patients with melanoma, lung adenocarcinoma, or kidney cancer have a 20%–40% response rate to ICB (5). Unfortunately, the majority of patients with these and other types of cancer remain refractory to ICB. One key determinant of sensitivity to immunotherapies is the abundance of tumor-infiltrating CD8+ T cells (6), and tumors can be stratified into T cell–inflamed or non–T cell–inflamed tumors based on the degree of T cell infiltration (7). Importantly, non–T cell–inflamed tumors appear to have decreased sensitivity to immunotherapies compared with T cell–inflamed tumors across human cancer, a concept we recently modeled in genetically engineered mice (8, 9). Thus, there is an urgent need to understand how T cell infiltration is controlled in tumors.

Pancreatic ductal adenocarcinoma (PDA) is predicted to become the second leading cause of cancer-related death and is largely refractory to existing therapeutic interventions, including immunotherapies (10), primarily due to the immunosuppressive tumor microenvironment (TME) and minimal T cell infiltration in PDA (8, 11, 12). Importantly, we and others found that neither mutational load nor number of predicted neoantigens accounted for variation in the abundance of tumor-infiltrating T cells (9, 13, 14). Instead, recent work has pointed to the critical importance of tumor cell–intrinsic factors — secreted factors, signaling pathways, and epigenetic status — in shaping the tumor immune microenvironment in both PDA (8, 11, 12, 15, 16) and other tumor types (17–22). One important conclusion from these studies is that multiple mechanisms contribute to the heterogeneity of immune infiltration.

In preclinical studies, we demonstrated the efficacy of a combination therapy, including chemotherapy, agonistic CD40, and ICB, in a genetically engineered mouse model of PDA (23, 24). Similarly to what occurred with patients, only some mouse PDA tumors responded well to the combination immunotherapy, while others were resistant; importantly, the abundance of tumor-infiltrating activated CD8+ T cells predicted the sensitivity to therapy (8). These studies provide a rationale for identifying factors that augment the intratumoral presence of activated CD8+ T cells, thereby synergizing with immunotherapy and improving the clinical outcome of PDA.
In this study, we took an unbiased approach to identifying tumor cell–intrinsic factors that shape the immune TME. We found that the expression of ephrin-A receptor 2 (EPHA2), a member of the EPH family of receptor tyrosine kinases, is negatively correlated with the degree of T cell infiltration in PDA and that deletion of Epha2 in tumor cells resulted in an increase in T cell infiltration and conferred sensitivity to immunotherapy. Mechanistically, we found that these effects were mediated through EPHA2/TGF-β/SMAD axis–dependent activation of prostaglandin endoperoxide synthase 2 (Ptgs2). The Ptgs2 protein encoded by this gene is a potent proinflammatory enzyme known colloquially as cyclooxygenase 2 (COX-2). These results provide a basis for targeting immunosuppressive signals arising from the tumor cells as a sensitization strategy for successful immunotherapy.

Results

Expression of EPHA2 inversely correlates with CD8+ T cell infiltration in PDA. To reveal signaling pathways that may suppress the infiltration of CD8+ T cells in PDA, we identified 742 genes whose expression correlated inversely with CD8A transcript abundance in The Cancer Genome Atlas (TCGA) data set (Figure 1A). Pathway analysis of this group of genes indicated activation of EPH/ephrin signaling as one of the top 5 gene signatures associated with the T cell–noninflamed phenotype (Supplemental Figure 1A and Figure 1B) and identified EPHA2 as the most highly expressed EPH family member in human PDA (Figure 1C). EPH proteins are a highly conserved family of receptor tyrosine kinases that function in development, particularly in neurogenesis and angiogenesis, and regulate a pleiotropic set of cellular functions. EPHA2 is overexpressed in multiple tumor types, and its expression correlates with poor prognosis and therapy resistance (25). Importantly, the mRNA expression level of EPHA2 negatively correlated with CD8A, CD3, PRF1, and GZMB, but not IFNG, in 2 independent data sets of human PDA samples (Figure 1D and Supplemental Figure 1, B and C). Moreover, EPHA2 expression was inversely correlated with patient survival (Figure 1E), consistent with previous studies showing that a high abundance of tumor-infiltrating T cells is associated with survival in human PDA (26–28). These results suggest that EPHA2 expression inversely correlates with T cell infiltration in human PDA and may have clinical significance.

We recently reported a library of congenic pancreatic tumor cell clones that faithfully recapitulate the heterogeneity of immune cell infiltration in PDA (8). Specifically, clones fell into 2 categories: T cell–high tumor cell clones, which generate implanted tumors with tumor-infiltrating T cells and a paucity of suppressive myeloid cells, and T cell–low tumor cell clones, which generate tumors with the opposite representation of immune cells (Supplemental Figure 1D). In this experimental system, Epha2 was again the top expressed gene in the Eph family (Figure 1F), and it was expressed predominantly in tumor cells (marked by yellow fluorescent protein [YFP]) as compared with YFP-negative nontumor cells (Figure 1G). Moreover, Epha2 mRNA and the proportion of EPHA2+ cells were higher in subcutaneous tumors derived from T cell–low tumor cells versus T cell–high tumor cells (Figure 1, H and I). Based on this strong correlation between EPHA2 expression and a paucity of tumor-infiltrating CD8+ cells in both murine and human PDA, we hypothesized that EPHA2, expressed by cancer cells, regulates immune infiltration in pancreatic cancer.

Tumor cell–intrinsic Epha2 regulates T cell infiltration and sensitivity to immunotherapy. To test this hypothesis, we investigated the effect of Epha2 deletion on the TME using our congenic mouse PDA tumor cell clones. Utilizing the CRISPR-Cas9 technique, we generated Epha2-KO tumor cells from 2 T cell–low tumor cell clones, 6419c5 and 6694c2 (Epha2-WT) (Supplemental Figure 2, A and B). Epha2 ablation in these clones resulted in a significant increase in CD3+ T cells in subcutaneously implanted tumors, both in terms of absolute numbers and as a percentage of CD45+ cells (Figure 2, A–C). Flow analysis showed that Epha2-KO tumors had increased proportions of total and activated CD8+ T cells, total CD4+ T cells, and further subsets (Figure 2, C–E), but decreased proportions of total myeloid cells and granulocytic myeloid-derived suppressor cells (gMDSCs, Figure 2F). Moreover, Epha2-KO tumors had increased CD8+/myeloid cell ratios (Supplemental Figure 2C), but no change in the number of macrophages or dendritic cells (Supplemental Figure 2D). We confirmed these results in orthotopically implanted tumors (Figure 2, G and H, and Supplemental Figure 2, E and F). The immunosuppressive character of gMDSCs in this model was shown by functional assays in our previous studies (11, 29). We confirmed by flow cytometry that in Epha2-KO tumors, the gMDSCs and macrophages exhibit a phenotype consistent with immunosuppressive function (Supplemental Figure 2, G and H). Interestingly, the expression of fibroblast marker PDGFRβ, but not α–smooth muscle actin (αSMA), was increased in Epha2-KO tumors (Supplemental Figure 2I). In addition, the proportions of Ki67–expressing YFP+ tumor cells and tumor weights were decreased in Epha2-KO tumors (Supplemental Figure 2, J–L). These results indicate that Epha2 expression by pancreatic cancer cells promotes the establishment of an immune TME dominated by myeloid cells and a paucity of tumor-infiltrating T cells.

We recently demonstrated that, compared with T cell–high tumors, T cell–low tumors have decreased sensitivity to a combination of chemo- and immunotherapy, GAFCP (gemcitabine [G], nab-paclitaxel [A], anti-CD40 agonist [F], anti-CTLA-4 [C], and anti-PD1-1 [P]; refs. 8, 23, 24). Given that Epha2 KO converted parental (T cell–low) tumors to the T cell–inflamed phenotype, we then tested Epha2 KO tumor sensitivity to the combination therapy. Ablation of Epha2 in cancer cells significantly improved the therapeutic efficacy of GAFCP with respect to tumor growth and overall survival (Figure 3, A–C). Collectively, these experiments suggest that EPHA2 expression in cancer cells promotes an immunosuppressive TME that confers resistance to combination immunotherapy.

Transcriptional profiling identifies Ptgs2 as a potential tumor cell–intrinsic regulator of the TME. To identify tumor cell–intrinsic factors mediating these Epha2-dependent phenotypes, we performed RNA-Seq and differential gene expression analysis of sorted tumor cells from subcutaneously implanted Epha2-WT and Epha2-KO tumors (Figure 4A). Gene set enrichment analysis (GSEA) revealed that Epha2-KO tumors exhibit a signature of IFN response and inflammatory pathways, similar to gene signatures observed in T cell–high tumor cells (Supplemental Figure 3, A and B, and ref. 8). Immunostaining for STAT1 confirmed the activation of IFN signaling pathways in Epha2-KO tumors (Supplemental Figure 3C).
focused on the genes enriched in both Epha2-WT tumor cells (compared with Epha2-KO) and T cell–low tumor cell clones (compared with T cell–high tumor cell clones) to identify candidate tumor cell–intrinsic factors. This approach yielded 17 genes that were expressed by tumor cells and significantly associated with an immunosuppressed TME in both T cell–low tumor cell lines (Figure 4, B and C, and not shown). Furthermore, we performed differential gene expression analysis of human T cell–low and T cell–high PDA tumors based on the top and bottom 20% expres-
expression of CD8A and found that 3 of these 17 genes — CCK, MACCI, and PTGS2 — were also significantly enriched in human T cell–low tumor samples (Supplemental Figure 3G). Among these 3 genes, Ptg2 was the most highly expressed gene in sorted T cell–low tumor cells from implanted mouse T cell–low tumors (base mean = 2189.05; Figure 4D), compared with the other 2 genes (Cck base mean = 15.3051, Macc1 base mean = 56.7993). While PTGS2 expression was not different between T cell cytolytic activity–high and –low human PDA samples (Figure 4E), patients with PTGS2 expression in the lower decile had significantly improved survival (Figure 4F). These results suggest that PTGS2 expression correlates with a T cell–low tumor phenotype and improved survival across species.

TGF-β signaling has been reported to regulate PTGS2 expression in tumors (30, 31). Hypergeometric Optimization of Motif EnRichment (HOMER) analysis predicted SMAD3 as one of the top transcriptional regulators in Epha2–WT tumor cells (Figure 4G), and GSEA analysis revealed a TGF-β signaling signature as greatly depleted in Epha2–KO tumor cells (Figure 4H), raising the possibility that TGF-β signaling regulates Ptg2 expression in our murine tumor system. To test this possibility, we first exposed murine PDA tumor cells to TGF-β in vitro,
mediated modulation of TME occurs through TGF-β/SMAD3–dependent regulation of PTGS2. Mice with a pancreas-specific deletion of Ptgs2 have suppressed tumor growth. To investigate the role of PTGS2 in PDA in its anatomical niche, we next engineered a biallelic deletion of Ptgs2 in the pancreatic epithelial cells of KPCY mice using homozygous floxed Ptgs2 alleles (KPCY PTGS2, Figure 5A). KPCY mice recapitulate salient features of human PDA, including the molecular, clinical, and histological features of disease, with 100% penetrance (31). We confirmed loss of Ptgs2 expression in the epithelial cells of KPCYptgs2 mice by immunohistochemistry (Figure 5B) and then followed cohorts of KPCY and KPCYptgs2 mice clinically and by ultrasound, comparing tumor onset and overall survival (Figure 3).

which uniformly resulted in an upregulation of Ptgs2 (Figure 4I). Next, we performed CRISPR-Cas9–mediated KO of Smad3 or Smad4 in a T cell–low tumor clone (Supplemental Figure 3H). This resulted in a significant decrease in the expression of Ptgs2 (Figure 4J) and a corresponding change in T cell and myeloid populations following subcutaneous implantation (Figure 4, K and L), consistent with a conversion to a T cell–high (or EphA2-KO) phenotype. Interestingly, TGF-β treatment also led to an increase in the cell-surface expression of EPHA2 (Supplemental Figure 3I), while Smad3 or Smad4 KO led to a decrease in EPHA2 expression in vitro and in vivo (Supplemental Figure 3, J and K), suggesting that a positive feedback loop may regulate EPHA2 levels. Collectively, these data suggest that EPHA2-mediated modulation of TME occurs through TGF-β/SMAD3–dependent regulation of PTGS2.

Mice with a pancreas-specific deletion of Ptgs2 have suppressed tumor growth. To investigate the role of PTGS2 in PDA in its anatomical niche, we next engineered a biallelic deletion of Ptgs2 in the pancreatic epithelial cells of KPCY mice using homozygous floxed Ptgs2 alleles (KPCYptgs2, Figure 5A). KPCY mice recapitulate salient features of human PDA, including the molecular, clinical, and histological features of disease, with 100% penetrance (31). We confirmed loss of Ptgs2 expression in the epithelial cells of KPCYptgs2 mice by immunohistochemistry (Figure 5B) and then followed cohorts of KPCY and KPCYptgs2 mice clinically and by ultrasound, comparing tumor onset and overall survival (Figure 3).
Figure 4. PTGS2 is a potential tumor cell–intrinsic regulator of TME. (A) Heatmap of differentially expressed genes in Eph2-WT and Eph2-KO tumor cells from subcutaneously implanted tumors from indicated clones (n = 3–8/group). (B) Overlap of the genes enriched in Eph2-WT (vs. Eph2-KO) and T cell–low (vs. T cell–high) tumors. (C) Seventeen coenriched genes identified (B) in Eph2-WT and Eph2-KO tumor cells from subcutaneously implanted mouse tumors (clone 5694c2). (D) Boxplot of Ptgs2 gene expression (tpm) in mouse tumor cells of subcutaneously implanted mouse tumors (n = 8/group). (E) PTGS2 expression in human PDA samples in the upper and lower deciles of cytolytic index (n = 14/group). PDA samples retrieved from the TCGA data portal. (F) Survival of patients in the upper and lower deciles of PTGS2 expression (n = 17/group; TCGA PDA data set). (G) HOMER analysis of promoter regions of differentially expressed genes. Prediction of transcriptional regulators enriched in Eph2-WT and Eph2-KO tumor cells (n = 3–8/group). (H) TGF-β signaling GSEA in Eph2-WT versus Eph2-KO tumor cells (n = 3–8/group). (I) Relative expression of Ptgs2 mRNA in PDA tumor cells treated with either PBS or TGF-β for 72 hours. Data from n = 5 independent experiments. (J) Relative expression of Ptgs2 mRNA in control (ctrl, empty vector transduced) and Smad3- and Smad4-KO 6419c5 PDA tumor cell lines. Data from n = 4 independent experiments. (K and L) Flow cytometric analysis of immune cell populations in control and Smad3-KO and Smad4-KO tumors (n = 8–10/group). (D, J–L) Data are presented as boxplots, with horizontal lines and error bars indicating mean and range, respectively. (E) Data are presented as mean with error bars indicating SEM. Statistical differences determined by Students’ t test (D and E) or 1-way ANOVA with Tukey’s HSD post test (J–L). The log-rank P value was calculated using GraphPad Prism (F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Ablation of tumor cell–intrinsic Ptgs2 promotes a T cell–low TME in PDA. To further explore the effect of tumor cell–intrinsic PTGS2 on the TME in PDA, we performed gain-of-function experiments by overexpressing Ptgs2 in T cell–high tumor cell lines (Ptgs2-OE, Figure 7A). Ptgs2 overexpression resulted in decreased infiltration by CD3+ T cells in the TME (Figure 7, B–D). The proportions of CD4+ and CD8+ T cells as well as the percentages of activated CD8+ T cells were significantly lower in Ptgs2-OE tumors (Figure 7D). Moreover, Ptgs2 overexpression increased the proportions of infiltrating myeloid cells, especially gMDCs, with a concomitant decrease in dendritic cell populations (Figure 7, E and F). To further assess whether tumor cell–intrinsic PTGS2 suppresses the response of PDA tumors to immunotherapy, we treated parental T cell–high tumors and Ptgs2-OE T cell–high tumors with the combination chemotherapy. Overexpression of Ptgs2 completely abolished the response to therapy in both T cell–high cell lines, resulting in loss of tumor growth control and decreased survival in the Ptgs2-OE tumors (Figure 7G and Supplemental Figure 6). Together, these results support the conclusion that tumor cell–intrinsic PTGS2 promotes a T cell–low TME in PDA and consequently confers resistance to immunotherapy.

Pharmacological inhibition of PTGS2 reverses PDA resistance to immunotherapy. Finally, we sought to determine whether the pharmacological inhibition of PTGS2, alone or in combination with immunotherapy, would affect the growth of established tumors. PTGS2-sufficient tumor-bearing mice (day 18 after implantation) were randomly assigned to the following treatment arms: (a) i.p.
Figure 5. Ptgs2 deletion suppresses PDA growth. (A) Graphic representation of pancreatic epithelial cell Ptgs2-deficient KPCY mouse. (B) PTGS2 protein staining (brown) in pancreatic ductal epithelial cells (arrows) of non-tumor-bearing mice (3–4 mice/group). Original magnification, ×20. (C) Kaplan-Meier curves of tumor-free (left) and overall survival (right) of KPCY and KPCY^Ptgs2^ mice. Number of mice per group indicated in parentheses. (D) Extracellular prostanoid levels measured in control (nontarget shRNA transduced) cell lines cultured for 72 hours (n = 6/group). (E) Relative expression of Ptgs2 mRNA (left) and PGE2 levels (right) in control (same as in D) and Ptgs2-KD (Ptgs2 shRNA) KPCY cell lines after 72 hours in culture (n = 6/group). (F) Control and Ptgs2-KD KPCY cell lines injected in syngeneic CY mice receiving either isotype control (IgG) or anti-CD4– and anti-CD8–depleting antibodies (aCD4/aCD8; n = 8–9/group): tumor-free survival (left) and tumor growth (right). (G) Control and Ptgs2-KD KPCY cell lines injected in syngeneic CY mice on regular chow (control) or 100 mg/kg celecoxib diet starting day 0 (ctrl + X; n = 9–12/group): tumor-free survival (left) and tumor growth (right). (H) Control (Cas9 only transduced) and Ptgs2-KO (Cas9/Ptges2 gRNA transduced) KPC cell lines injected in WT mice receiving either isotype control (IgG) or anti-CD4– and anti-CD8–depleting (aCD4/aCD8) antibodies (n = 5–9/group): tumor-free survival (left) and tumor growth (right). (D and E) Data are presented as boxplots, with horizontal lines and error bars indicating mean and range, respectively. Statistical significance measured by Student’s unpaired t test (E). The log-rank P values for C were calculated in GraphPad Prism. Statistical analyses of tumor growth and survival for (F–H) performed using linear mixed-effects model with Tukey’s HSD post test using the lme4 and the survival package in R. *P < 0.05; **P < 0.01; ****P < 0.0001.
therapy significantly increased the survival of autochthonous tumor-bearing KPCY mice compared with the untreated mice (Figure 8C). These results demonstrate that pharmacological inhibition of PTGS2 sensitizes PDA to immunotherapy.

**Discussion**

Although the extent of passenger mutations in human cancers is a well-recognized determinant of response to checkpoint blockade immunotherapy, there is an increasing appreciation that heteroge-
Figure 7. Tumor cell–intrinsic Ptgs2 promotes T cell–low TME and resistance to immunotherapy in PDA. (A) Relative expression of Ptgs2 mRNA measured by qPCR in T cell–high PDA tumor cell clones transduced with either empty vector (EV) or pCDH-FHC vector carrying mouse Ptgs2 gene for overexpression (Ptgs2-OE). Representative data from n = 3 independent experiments. (B and C) Representative immunofluorescent staining images (B) and quantification (C) of CD3+ T cells in 2838c3-EV and 2838c3-Ptgs2-OE subcutaneous tumors (n = 5/group): CD3 (red), YFP (green), and DAPI (blue). Original magnification, ×20. (D–F) Flow cytometric analysis of subcutaneously implanted empty vector or Ptgs2-OE tumors from indicated clones (n = 5–7/group). (G) Parental and Ptgs2-OE T cell–high tumor growth and mouse survival with or without GAFCP treatment. Tumor cells implanted subcutaneously into C57BL/6 mice (n = 5–8/group). GAFCP treatment started 9 days after implantation at 3–5 mm tumor diameter. (A, C–F) Data are presented as boxplots, with horizontal lines and error bars indicating mean and range, respectively. Statistical analysis between 2 groups calculated using Student’s unpaired t test (C–F). The log-rank P values for Kaplan-Meier curves in G were calculated using GraphPad Prism. Statistical analysis of tumor growth curves performed using linear mixed-effects model with Tukey’s HSD post test using lme4 and the survival package in R (G). *P < 0.05; ***P < 0.001.
neous cancer cell-intrinsic properties apart from neoepitopes fundamentally regulate host immune response and the extent of tumor T cell infiltration (8, 17, 18, 20, 22, 32, 33). Across TCGA, the correlation between tumor mutational burden and a T cell–inflamed gene expression profile is poor (9, 13). Here, we identify EPHA2 and PTGS2 as tumor cell–intrinsic factors that regulate immune infiltration in the TME and modulate response to immunotherapy.

EPH receptor tyrosine kinases were first identified for their role in development, but several family members—including EPHA2—also play a prominent role in malignancy. EPHA2 has been reported to promote tumor cell growth, migration, and metastasis as well as drug resistance in multiple types of malignancies (34–40). In PDA, increased EPHA2 expression has been associated with poor clinical outcomes (41–45).

We observed that expression of EPHA2 inversely correlates with the abundance of CD8+ T cells in human and murine PDA tumors. Although we had previously identified CXCL1 as a determinant of CD8+ cell exclusion in PDA (8), we observed no correlation between EPHA2 and CXCL1 expression levels in the human PDA TCGA data set (n = 179, Pearson’s r = −0.04, P = 0.618). In addition, Cxcl1 was not differentially expressed in the mouse Epha2-WT and Epha2-KO tumor cell RNA-Seq data set (n = 3–8/group, P = 0.302). We functionally validated the role of EPHA2 in controlling immune infiltration and response to immunotherapy, changing our understanding of EPHA2 as an oncogene and an alternative determinant of tumor immunosuppression. Interestingly, EPHA2 overexpression has been associated with resistance to MAPK inhibition in melanoma, in which resistance was accompanied by a decrease of tumor-infiltrating CD8+ T cells (46). Similarly, molecular signatures of MAPK inhibitor–resistant tumors are shared across melanoma patients resistant to ICB (47).

Deletion results in the suppression of tumor cell–intrinsic SMAD signaling, suggesting a role for SMADs in modulating the immune infiltrate in PDA tumors. While we did not observe differential expression of TGF-β between Epha2-WT and Epha2-KO, it is possible that tumor cells utilize stromal TGF-β to upregulate SMAD signaling. This notion is supported by recent studies demonstrating that TGF-β signaling in cancer-associated fibroblasts (CAFs) prevents intratumoral T cell infiltration and suppresses the response to ICB (48, 49). However, in PDA, TGF-β is also shown to suppress IL-1-induced JAK/STAT signaling and tumor-promoting inflammatory CAF phenotype (50). Moreover, defective TGF-β signaling in mice is associated with accelerated progression of squamous cell carcinoma (51), indicating tissue- and cell context–dependent effects of TGF-β signaling. The results presented here deepen our understanding of the role of TGF-β and SMAD signaling in tumor immunity and suggest, as illustrated in Supplemental Figure 6B, that tumor cell–intrinsic determinants of the immune TME may act by establishing complex patterns of crosstalk between tumor cells and the surrounding stroma.

We have demonstrated that deletion of Epha2, Smad3, or Smad4 decreased the expression of Ptgs2, the gene that encodes the COX-2 enzyme, resulting in reduced levels of proinflammatory PGE2. While the Ptgs2 promoter region does not have the SMAD-binding motif (52), its transcriptional activators ETS and API are enriched with SMAD3-binding sites (53, 54). Both COX-2 and PGE2 have been implicated in tumor progression (55), mainly as mediators of angiogenesis and tumor cell proliferation and survival (56, 57). Importantly, elevated PTGS2 levels have been linked to unfavorable disease-free survival, larger tumor size, and higher metastatic incidence in breast, gastrointestinal, and colorectal cancers (58–62). It has been shown that in viral infections, PGE2,
acting through EP2 and EP4 receptors, can impair cytotoxic T cell function and survival (63). We have previously shown that targeting either tumor-intrinsic or myeloid cell Ptgs2 modulates immune infiltration and relieves immunosuppression, resulting in tumor growth inhibition, in a mouse model of breast cancer (64-67) As shown by others, genetic ablation of PGE2-producing enzymes suppresses the growth of melanoma cells in mice by increasing the presence of cDC1s in the TME (68, 69). These studies support our finding that Ptgs2 plays a critical role in antitumor immune suppression.

PTGS2 expression is highly upregulated in human PDA (61) and mutant KrasG12D-driven mouse models of PDA (70-72). Ablation of Ptgs2 expression in pancreas is associated with enhanced Kras expression and accelerated PanIN formation (73) as well as increased macrophage presence in PDA (70). Consequently, absence of Ptgs2 delays PDA development in Pdx1; KrasG12D/+; Ptenfr/+ mice, and the overexpression of Ptgs2 promotes early onset and progression of PDA (70). The tumor-promoting effects of PTGS2 have been attributed to its ability to induce signaling pathways downstream of RAS (73), PI3K/AKT (72), and ERK (70). Here, we demonstrate that a modest decrease in Ptgs2 expression translates into a substantial suppression of PGE2 production and, as a result, higher immune cell infiltrate and cytolytic activity in PDA. Our study suggests that the immunosuppressive functions of PTGS2 may have contributed to the tumor immune evasion and poor survival.

In summary, this study identifies an EPHA2/TGF-β/SMAD/PTGS2 signaling axis as a pathway deployed by PDA tumor cells to establish T cell–low TME (Figure 8D). Apart from its oncogenic potential, activation of this axis also frustrates response to immune therapy. Consequently, ablation of EP2A or PTGS2 reverses T cell exclusion and sensitizes tumors to immune therapy, even in the absence of strong neoepitopes. These findings not only predict which patients with pancreatic cancer might respond to novel immunotherapy combinations — such as a phase II study of chemotherapy, CD40, and PD1 agents currently underway (ClinicalTrials.gov NCT03214250) — but also suggest a potential role for selective inhibitors of PTGS2, TGF-β, or EP2A as additional components of future combination therapies.

Methods

Animals. All WT C57BL/6 mice were purchased from The Jackson Laboratory and/or bred at the University of Pennsylvania. KrasLSL-G12D/+; Pdx1-Cre, and Rosa-LSL-YFP (KPCY) mice (74, 75) were bred in-house, backcrossed for over 10 generations with C57BL/6J mice (Jackson Laboratories), and assessed at the DartMouse Speed Congenic Core facility at the Geisel School of Medicine at Dartmouth College (Hanover, New Hampshire, USA). KPCY mice were then crossed with C57BL/6 mice with loxp sites (flox/flox) inserted in introns 5 and 8 of the Ptgs2 gene (76) to generate KPCYfloxtg mice. Seven-to-eight-week-old tamoxifen-inducible Cre+/+Ptgs2fl/fl mice (77) provided in house were treated with 100 mg tamoxifen (Sigma-Aldrich) for 5 days to generate Ptgs2 conditional knock-out (cKO) mice. For the survival studies, young (less than 10 weeks old), KPCY and KPCYcKO mice were monitored for the development of pancreatic tumors by abdominal palpation. After 10 weeks, all mice were monitored by ultrasound imaging (Vevo 2100 Imaging System with 55MHz MicorScan transducer, Visula Sonics) once a week until tumor discovery, after which the tumor growth was monitored by biweekly ultrasound imaging. For tumor-bearing mice, end point criteria included tumor volume exceeding 500 mm3, severe cachexia, or weakness and inactivity.

Tumor cells. KPCY and KPC cell lines were derived from single-cell suspensions of PDA tissues as previously described (78) and tested by the Research Animal Diagnostic Laboratory (RADIL) at the University of Missouri (Columbia, Missouri, USA), according to the Infectious Microbe PCR Amplification Test (IMPACT) II profile. All mouse pancreatic tumor cell clones were isolated from late-stage primary tumors from KPCY mice on a C57BL/6 background and generated by limiting dilution (Supplemental Table 1). Cells were cultured in DMEM (high glucose without sodium pyruvate) with 10% FBS (Gibco; Thermo Fisher Scientific) and glutamine (2 mM). The clones were regularly tested using the MycoAlert Mycoplasma Detection Kit (Lonza).

Analysis of TCGA and ICGC data sets. Data showing the expression levels of CD8A and EP2A genes in human PDA tumors were downloaded from TCGA. The gene expression profiles of these samples were downloaded and processed for transcripts per million (tpm), as previously described (79). Pearson’s correlation analysis was used to determine R2 values and P values. All correlation analysis resulted in P values of less than 0.0001, identified as significant. Patient survival and normalized RSEM counts (rsem.genes.normalized_results) for tumor PTGS2 and EP2A were retrieved from the RNA-Seq analysis of PDAC patients in the TCGA database, using the OncoLnc tool (80). The log-rank P values were calculated for the upper and lower deciles (n = 17/group) of PTGS2 and EP2A expression (TCGA data as of July 2018), using GraphPad Prism7. Differential PTGS2 expression in cytolytic low and high tumors was analyzed with RNA-Seq data for PDA samples retrieved from the TCGA data set. Length-scaled tpm counts were determined using output from kallisto version 0.43.0 with default parameters. The reference transcriptome was retrieved from Ensembl in December 2017 (release 90). Cytolytic index was calculated for all samples, as previously described (14). Samples with a cytolytic index equal to or more extreme than the top and bottom deciles were used in the differential gene expression analysis. Gene-level differential expression for PTGS2 was determined using the DESeq2 package with default parameters and the Benjamini-Hochberg correction (81). Metascape analysis was done, using default parameters (http://metascape.org/gp/index.html#/main/step1). Output results from the online Metascape analysis were graphed using GraphPad Prism.

Analysis of RNA-Seq, differential gene expression, and GSEA molecular signature analysis. RNA samples were extracted from sorted YFP+ tumor cells from subcutaneously implanted tumors using the QIAGEN RNeasy Micro Kit following the manufacturer’s instructions. RNA was sent out to a commercial company (Novogene) for library preparation and high-throughput sequencing using Illumina sequencers to generate paired end 150 bp data. Fastq files were checked for quality using FastQC. Raw counts of gene transcripts were obtained using the alignment-independent tool Salmon, using standard settings (82). The raw count matrix was subsequently imported into R-studio (R version 3.3.3) and used as input for DESeq2 following the vignette of the package for normalization and differential gene expression analysis (83). Salmon was also used to normalize and quantitate gene expression in TPM through quantile normalization. Differentially expressed genes from DESeq2 analysis were used as input for MSigDB GSEA (83).
Lentiviral transduction of tumor cells for CRISPR-mediated ablation. The CRISPR vector, lentiCRISPR v2, was a gift from Feng Zhang (Massachusetts Institute of Technology, Cambridge, Massachusetts, USA) (Addgene plasmid 52961) (84). The vector and pSVsg and pSAX2 lentiviral packaging plasmids (Addgene) were cotransfected into 293T cells using PEI reagent. Lentiviral particles were collected 48 hours after transfection and filtered for usage. KPC cells transduced either with Cas9-Puro (control) or Cas9-guide-Puro (KO) were selected with 2 μg/ml puromycin. Single cells were picked from the KO cell line and expanded into clones. Deletion efficiencies were assessed by gene-specific quantitative PCR (qPCR) analysis. CRISPR sequences utilized were as follows: *Epha2-, AACAAGTTGATCCGCCGACC, Epha2-, BTTGCGTCTGGAAGCACGCAA, Ptg2a-, ATTCGAGACAGATCATAGCCG, Ptg2b-, BCCCATAGTCACATTGGTAGT, Smad3-, AGCTCCATGCGGGTGTTAATCT; Smad3-, AACCTACCGTAGATATTTGCTC; Smad4, AGCGAAGTATCGCGGCGAC and Smad4, BTCCGGTTGATGCCGGATTACT.

Lentiviral transduction of tumor cells for shRNA-mediated KD. KPCY cells were transduced with Mission pKO.1-puro Transduction Lentiviral Particles (Sigma-Aldrich) carrying either nontarget control shRNA or Ptg2 shRNA (KD) and selected with 2 μg/ml puromycin (Sigma-Aldrich).

Lentiviral transduction of tumor cells for overexpression of target genes. The pCDH-EF1-FHC vector was a gift from Richard Wood (MD Anderson Cancer Center, Houston, Texas, USA) (Addgene plasmid 64874) (85). The Ptg2 gene was cloned into the vector for constitutive overexpression. The vector and pSVsg and pSAX2 lentiviral packaging plasmids (Addgene) were cotransfected into 293T cells using PEI reagent. Lentiviral particles were collected 48 hours after transfection and filtered for usage. Tumor cells were transduced and selected with 2 μg/ml puromycin. Overexpression efficiencies were assessed by gene-specific qPCR analysis.

qPCR analysis for gene expression. RNA was prepared from cultured tumor cells or sorted cells from implanted tumors using the RNaseasy Mini Kit or the RNaseasy Micro Kit (QIAGEN). cDNA was generated using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). qPCR analysis was performed using SsoAdvanced SYBR reagent (Bio-Rad) and Bio-Rad qPCR Platform, and results were normalized to the expression of *Tbp*. Primer sequences used for qPCR were as follows: *Epha2, forward-GCAAGGGAAAGTGTTT; Epha2, reverse-CATGATAGGCGATGCTGTC; Ptg2a, forward-CATGATAGGCGATGCTGTC; Ptg2b, reverse-AGAACCTGTTGCGGTACCTCAT; Smad3, forward-CAGCGAGAACTGGAACAC; Smad3, reverse-GGCGAGTATAAGCTGAGGGA; Smad4, forward-ACACCAACAGAACTGACGCTG; and Smad4, reverse-GCAAGGGTTTACCCATCTGC.

For PCR reactions in Figure 4 and Supplemental Figure 4, total RNA from tumor cell lines was isolated (RNaseasy, QIAGEN) and reverse transcribed (Reverse Transcription Kit, Applied Biosystems) according to the manufacturer’s instructions. Real-time qPCR for *Ptg2* and 18S mRNA was performed using inventoried gene expression assays and TaqMan Universal PCR Master Mix (Applied Biosystems). PCR products were detected using the Vii A7 Real-Time PCR System (Applied Biosystems). Results were analyzed using the comparative Ct method and normalized to 18S RNA.

**PGE2 measurements.** Prostaglandins and their metabolites were measured by ultra-high-pressure liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS), using negative electrospray ionization and selected reaction monitoring (SRM) techniques on a Quantum Ultra interfaced to an Accela UHPLC system (Thermo Scientific), as described previously (67).

**Implantation of tumor cells.** Epha2-WT and Epha2-KO cultured tumor cells were dissociated into single cells with 0.25% trypsin (Gibco, Thermo Fisher Scientific), washed with serum-free DMEM twice, and counted in preparation for subcutaneous or orthotopic implantations. 1.5 × 10^6 to 3.0 × 10^6 Tumor cells were implanted subcutaneously, and 3.0 × 10^5 to 5.0 × 10^6 tumor cells were implanted orthotopically into 6- to 8-week-old C57BL/6 mice. Tumors were harvested 3 to 4 weeks following implantation. Control and Ptg2-KO were prepared as above. For tumor growth and survival studies, the cells were resuspended in sterile PBS, 1.0 × 10^6/100 μl, and injected subcutaneously in the flanks of T cell-replete or T cell-depleted C57BL/6 mice and female host mice. KPC control and Ptg2-KO were prepared as above. For tumor growth and survival experiments, 1.0 × 10^6/100 μl cells in 100 μl sterile PBS were injected into the flanks of 6- to 8-week-old T cell-replete or T cell-depleted female C57BL/6 mice or into the flanks of male and female tamoxifen-induced global Ptg2-KO (gKO) (77) hosts. For tumor flow cytometry, 4 to 5 × 10^4 cells/100 μl sterile PBS were injected into the flanks of 6- to 8-week-old female C57BL/6 mice. Tumor tissues were harvested and analyzed 12 to 13 days after implantation.

**Subcutaneous tumor growth and regression assessments.** For tumor growth kinetics, tumors were measured every 3 days. Tumor length and width were measured with calipers, and tumor volumes were then calculated as length × width^2/2. Tumor volumes of 500 mm^3 were used as an end point for survival analysis. Tumor regressions and waterfall plots were calculated using the initial tumor size at the start of treatment and tumor size 21 or 27 days later.

**Treatments and T cell depletions.** For experiments shown in Figure 2 and Supplemental Figure 2, gemcitabine (Hospira) and Nab-paclitaxel (Abraxane, Celgene) were purchased from the Hospital of the University of Pennsylvania Pharmacy. Gemcitabine was procured as pharmaceutical grade suspension at 38 mg/mL, diluted to 12 mg/mL in PBS, and administered at 120 mg/kg via i.p. injection. Abraxane was purchased as a pharmaceutical grade powder suspended at 12 mg/mL in PBS for i.p. injection at a dose of 120 mg/kg. Vehicle control mice received the equivalent to a nab-paclitaxel dose of human albumin (huAlb; MilliporeSigma). Chemotherapy was injected at days 9 to 14, when tumor size was 3 to 5 mm. For anti-CD40 agonist treatment, mice were injected i.p. with 100 μg of either agonistic CD40 rat anti-mouse IgG2a Ab (clone FGG45, endotoxin-free) or the isotype control IgG2a Ab (clone 2A3, BioXcell), administered 48 hours after chemotherapy. For checkpoint blockade treatment, mice were injected i.p. with 200 μg of PD-1 (clone RMP 1-14, BioXcell) and 200 μg CTLA4 (clone 9H10, BioXcell), starting at days 9 to 14 (therapy start time point), using 7 and 3 doses, respectively. Control mice received the isotype control IgG2a Ab (clone 2A3, BioXcell) on treatment days. For the experiments in Figure 4, CD4 and CD8 T cells were depleted using i.p. injections of 200 mg endotoxin-free anti-CD4 (clone GK1.5, BioXcell) and anti-CD8 (clone 2.43, BioXcell) antibodies 3 days prior to tumor implantation and twice a week thereafter, for the duration of the experiment. Control groups received IgG2b isotype control antibody (BioXcell). T cell depletion in the peripheral blood was confirmed by flow cytometry. In treatment groups, starting at day 18, mice received either 100 mg/kg/d celecoxib in chow.
intracellular stainings and the gating strategies are listed in Supplementary File. KPCY tumor-bearing mice with less than 40 mm³ tumors by ultrasound measurement were placed on a 50 mg/kg celecoxib diet together with anti-PD-1 antibody injections every third day starting from the day of diagnosis (8 doses of anti-PD-1 in total). The same mice received a single dose of aCD40 with the second dose of anti-PD-1.

Flow cytometry of implanted tumors. For the flow cytometric analyses, tumors were digested in 1 mg/ml collagenase with protease inhibitor (Sigma-Aldrich) and filtered through a 70 μm cell strainer. Samples were stained for cell-surface molecules then fixed and permeabilized (eBioscience Intracellular Fixation & Permeabilization Buffer Set, Invitrogen), further stained for intracellular targets, and analyzed by flow cytometry using the BD FACSCanto system (BD Biosciences) and Flow Jo software (Treestar). The antibodies used for cell-surface and intracellular stainings and the gating strategies are listed in Supplementary Tables 2, 3, 4, and 5.

Immunofluorescent and immunohistochemistry stainings. For CD3, PTGFRβ, and αSMA stainings, tissues were fixed in Zn-formalin for 24 hours and embedded in paraffin. Sections were deparaffinized, rehydrated, and prepared by antigen retrieval for 6 minutes each and then blocked in 5% donkey serum for 1 hour at room temperature, incubated with primary antibodies (Supplemental Table 6) overnight at 4°C, washed, incubated with secondary antibodies for 1 hour at room temperature, washed again, and mounted. Slides were visualized and imaged using an Olympus IX71 inverted multicolor fluorescent microscope and a DP71 camera. For CD3 quantification, stained cells were counted in 5 fields per sample. PTGFRβ and αSMA stainings were quantified with ImageJ software (NIH) using default settings. PTGFRβstaining was performed on Zn-formalin-fixed, paraffin-embedded pancreata using anti-PTGFRβ rabbit monoclonal antibody (Thermo Fisher Scientific). Slides were scanned with an Aperio CS-O scanner, and images were visualized using Aperio ImageScope software (Leica Biosystems).

In vitro treatment with IFN-β and IFN-γ for MHC I expression analysis. Cultured tumor cells were induced with 100 ng/mL of IFN-γ (Peprotech) and/or 1,000 units/mL IFN-β (PBL Assay Science) for 24 hours before analysis. Single cells were then stained with MHC I mAb (BioLegend) and analyzed by flow cytometry.

Data resources. The RNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus database (GSE120208).

Software. PRISM software and R were used for the data processing, statistical analysis, and result visualization (http://www.graphpad.com). The R language and environment for statistical computing and graphics (https://www.r-project.org) were utilized in this study for the statistical and bioinformatics analysis of RNA-Seq data. The R packages used for the analysis described in Methods were obtained from the Bioconductor (https://www.bioconductor.org) and CRAN (https://cran.r-project.org/web/packages/available_packages_by_name.html).

4. Sanmamed MF, Chen L. A paradigm shift in...